SYK vs VRTX: Which Stock Is the Better Buy?
Stryker Corporation and Vertex Pharmaceuticals Incorporated side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — SYK vs VRTX, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| Stryker Corporation (SYK) | Vertex Pharmaceuticals Incorporated (VRTX) | |
|---|---|---|
| Market cap | $124.9B | $121.1B |
| Revenue (latest FY) | $25.12B | $12.00B |
| Net income (latest FY) | $3.25B | $3.95B |
| Revenue growth (5y CAGR) | 11.8% | 14.1% |
| Net margin | 12.9% | 32.9% |
| Return on equity | 14.5% | 21.2% |
| P/E ratio | 37.7 | 28.3 |
| Dividend yield | 1.1% | — |
| Profitable years (of last 10) | 10 | 8 |
| Positive free cash flow | Yes | Yes |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full SYK vs VRTX breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open SYK's full financials → Open VRTX's full financials →More comparisons
Frequently asked questions
Which is bigger, SYK or VRTX?
Stryker Corporation is larger by market capitalization — $124.9B versus $121.1B.
Which grows faster, SYK or VRTX?
Over the last five fiscal years, Vertex Pharmaceuticals Incorporated grew revenue faster — 14.1%/yr versus 11.8%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.